doctors now have access to an alternative oral therapy – the first new oral option for more than 20 years. Eli Lilly and Boehringer Ingelheim’s Jardiance (empagliflozin) and related product ...
Boehringer Ingelheim and Eli Lilly's SGLT2 inhibitor Jardiance has become the first drug in the class to be approved in the EU for all adults with symptomatic chronic heart failure (CHF), giving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback